Maia Biotechnology Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
MAIA American 8731 https://maiabiotech.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Maia Biotechnology Inc

MAIA Biotechnology Announces $1.00 Million Private Placement - Apr 23rd, 2024 12:51 pm
MAIA Biotechnology to Present at Two Investor Conferences in April 2024 - Apr 5th, 2024 12:01 pm
MAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero - Mar 28th, 2024 7:00 pm
MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement - Mar 26th, 2024 7:00 pm
MAIA Biotechnology Announces $1.33 Million Private Placement - Mar 26th, 2024 12:01 pm
MAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private Placement - Mar 22nd, 2024 7:00 pm
MAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to its Scientific Advisory Board - Mar 21st, 2024 7:00 pm
Director Ngar Louie Acquires 170,940 Shares of MAIA Biotechnology Inc (MAIA) - Mar 16th, 2024 5:49 am
MAIA Biotechnology to Participate in the 36th Annual ROTH Conference - Mar 7th, 2024 2:45 pm
MAIA Biotechnology and Nationwide Children’s Hospital Announce Presentation of THIO’s Potency in Pediatric Brain Tumors at American Association of Cancer Research Annual Meeting - Mar 6th, 2024 4:04 pm
MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients - Mar 6th, 2024 1:48 pm
MAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates and Development Pipeline in Letter to Shareholders - Mar 5th, 2024 1:45 pm
MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor - Feb 27th, 2024 3:30 pm
MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer - Feb 22nd, 2024 3:30 pm
MAIA Biotechnology Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer - Feb 7th, 2024 1:01 pm
MAIA Biotechnology Announces Publication of International PCT Patent Application Covering Anticancer Telomere-Targeting Compounds - Jan 24th, 2024 12:15 pm
MAIA Soars 20% on Interim Results From Lung Cancer Study - Jan 18th, 2024 6:06 pm
MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024 - Jan 17th, 2024 2:00 pm
MAIA Biotechnology to Present at Biotech Showcase 2024 on January 9, 2024 - Jan 5th, 2024 1:00 pm
MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer - Dec 19th, 2023 12:00 pm